UNSPSC 51144125: Mefenorex

This classification denotes an anorexiant with the molecular formula C12H18ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K98M4N387W, chemically known as phenethylamine, n- (3-chloropropyl)-.alpha.-methyl-, hydrochloride but more generally known as mefenorex, which bears US NIH Compound Identifier 21777. European Medicines Agency schedules Mefenorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08706MIG. The term MEFENOREX is an International Non-Proprietary Name.

UNSPSC 51144125 Mefenorex, a Commodity code, nominally names a specific pharmaceutical agent, but recent state and local procurement activity under this code shows little relevant alignment. The three most recent opportunities tagged to the code—naloxone and drug deactivation systems procurement, a therapeutic pharmacy direct-to-manufacturer RFI, and a multistate generic pharmaceutical and OTC cooperative purchasing RFP—address public health pharmaceutical supply chains and pharmacy benefit administration broadly, not mefenorex specifically. State and local issuing bodies appear to be using the code as a general pharmaceutical-supply classifier rather than a specific-drug procurement marker. The solicitations span state health and human services agencies, county health departments, and multistate cooperative purchasing alliances, each managing drug acquisition, distribution, and benefit-management functions that extend well beyond a single active pharmaceutical ingredient.

Geographically, recent activity appears concentrated in Florida and Texas, with multistate cooperative participation extending the scope to Oregon and other member jurisdictions. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program operating outside traditional pharmacy benefit manager structures. The Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802, proposals due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities. The mismatch between the code's nominal scope (mefenorex, a specific sympathomimetic amine) and the actual procurement activity suggests the code is not a reliable predictor of future opportunities or vendor fit under its stated pharmaceutical classification.